Can Brian Druker develop another Gleevec at Blueprint Medicines?

A venture capital firm in Boston yesterday bet $40M in first round financing that Dr Druker and his partners can repeat the success of Gleevec/Glivec with a new Boston/Cambridge life sciences start-up company, Blueprint Medicines.

If Daedalus had money to invest, a wager on Dr Druker would be as good as any in the biotechnology industry.  After the successful development of Gleevec/Glivec, a tyrosine kinase inhibitor that Drs Druker & Lydon were instrumental in developing with Novartis for the treatment of chronic myeloid leukemia (CML), it’s hard not to believe that they cannot do it again.

Icarus Consultants’ Sally Church worked closely with Dr Druker while at Novartis Oncology. Starting in oncology new products she saw the potential of STI-571, and subsequently took the product to market in the U.S. market as Gleevec. We wish him well, and should Blueprint Medicines need any commercial, marketing strategy consulting services, we hope he’ll call us :).

You can read more on Biotech Strategy Blog.

, , , , , , , , , , , , , , , , , , , ,

error: Content is protected !!